In vivo Tumor Models

In vivo tumor xenograft models, including CDX, PDX, syngeneic hPBMC, HSC, immune checkpoint

WuXi Biology has significant experience in oncology drug discovery. We offer a large collection of tumors models for small and large molecule drug development, including:

Cell line-derived xenograft (CDX) tumor models
Patient-derived xenograft (PDX) tumor models
Syngeneic tumor models
Human immune checkpoint gene KI mouse models
hPBMC/HSC humanized models

Cell line-derived xenograft (CDX) tumor models

320+ validated models, covering 30 cancer types
77+ cell lines derived from PDX models
Imaging-based orthotopic/metastatic tumor models
Brain/bone metastatic models of lung/breast cancer cell lines
Validated models for efficacy testing of antibody-drug conjugates (ADCs)
Extensive panel of c-MET related CDX models

41 luciferase labeled orthotopic/metastatic tumor models

Covering 17 tumor types
Bioluminescent imaging system
Specific-pathogen-free (SPF) barrier

Patient-derived xenograft (PDX) tumor models

1,400+ PDX models covering full range of cancer types
Fully-characterized models with genetic, molecular and pharmacological profiling
Drug-resistant PDX models available
in vitro screening and derivative PDXC/PDXO models
Validated models for efficacy testing of antibody-drug conjugates (ADCs)
Extensive panel of c-MET related PDX models
PDX panel with hPBMC humanization

Syngeneic tumor models

87 syngeneic models (mouse, rat, hamster)
Comprehensive panel of orthotopic syngeneic tumor models
Responsiveness to immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4)
Tumor-infiltrating leukocytes (TILs) map
WES, RNA-seq and scRNA-seq characterization

hPBMC/HSC humanized models

hPBMC Humanized Models

Established models for immune-checkpoint inhibitor and bi-specific antibody candidates in a human-resembling immune system.
Annotation for both immune cells (phenotyping, biomarker, functions) and tumor cells (expression, mutation)
Different PBMC delivery systems (systemic injection or co-inoculation with tumor)

HSC Humanized Models

Available humanized models from CIEA combined with WuXi PDX/CDX models.
Customizable with human cytokine transgenic mice (GM-CSF/hIL-3 or hIL-2) to improve the reconstitution of myeloid lineage.

Established CDX/PDX-hPBMC Models

Genetically engineered models

48 engineered cell lines based on construct overexpression or gene knock-in
Pharmacologically validated in vitro and in vivo
Focusing at drug-resistant mutation introduction and IO-related checkpoint humanization
Example targets: EGFR, ROS1, ALK, RET, FLT3, BTK, Claudin18.2, PD-L1

Human immune checkpoint gene KI mouse models

KI (Knock-in) mice offer the possibility to study checkpoint antibodies targeting human checkpoints in the context of a fully functional immune system.